Solid Biosciences (SLDB)
(Delayed Data from NSDQ)
$8.06 USD
+0.34 (4.40%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $8.12 +0.06 (0.74%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
SLDB 8.06 +0.34(4.40%)
Will SLDB be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SLDB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SLDB
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
SLDB: What are Zacks experts saying now?
Zacks Private Portfolio Services
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
Other News for SLDB
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences transferred with Overweight rating at Piper Sandler
Solid Biosciences price target lowered by $2 at JPMorgan, here's why
PTC Therapeutics rallies 18% on EU authorization update for Translarna
Buy Rating for Solid Biosciences Anchored on Robust Financials and Promising Clinical Prospects